CURRICULUM VITAE – STUART BURSTEN, MD, FACP

EDUCATION

High School

Southwest High School 1971

Kansas City, MO

(Salutatorian,

National Merit Scholar)

College

Stanford University B.S., Biology (Honors, highest distinction) 1975

Palo Alto, CA A.B., Psychology (Highest distinction)

Medical School

Yale University School of Medicine; M.D., Medicine 1980

New Haven, CT

Thesis (awarded Honors): A clinical scoring system for detection of

Patients with pheochromocytoma

POST GRADUATE TRAINING

Boston City Hospital: intern, internal medicine 1980-1981

Boston, MA

University of Washington: resident, internal medicine 1981-1983

Seattle, WA

University of Washington,: fellow, nephrology 1983-1985

Seattle, WA

University of Washington: post-doctoral research fellow 1985-1986

Seattle, WA

BOARDS

American Board of Internal Medicine, Internal Medicine 1983

American Board of Internal Medicine, Nephrology 1990

Recertification (ongoing) 2008-2010

HONORS (Selected)

National Merit Foundation Scholarship (1st in Midwest, 3rd in country) 1971

National Grocers Association Scholarship 1971

S & H Green Stamps Association Scholarship 1971

National Science Foundation Award 1974

House Associate Award, Stanford University 1974-1975

NIH Training Program Grant (MD-PhD) 1975-1978

Northwest Kidney Foundation Fellowship 1983-1984

HONORS (SELECTED) CONT.:

National Institute of Arthritis, Diabetes, Digestive, and Kidney 1985-1986

Disease Fellowship (at U of W)

Associate Investigator, Dept. of Veterans Affairs 1986-1988

Northwest Kidney Foundation Research Awards 1988-1989

1989-1990

1991-1992

Research Associate, Department of Veteran Affairs, Career 1989-1992

Development Award

Who’s Who in American Medicine 1993

Who’s Who in American Science 1994

Who’s Who in American Business 1994

Who’s Who in World Science 1998

Who’s Who in the World (Millennium) 2000

Who’s Who in American Science (Millennium) 2000

Who’s Who in Finance and Industry (Millennium) 2000

Fellow, American College of Physicians, Direct Election 2000

LICENSURE

Washington State 1981

MD00019512

Colorado 2001

MD39320

California 2001-present

Certificate #G86125

Georgia

MD82454

SOCIETIES

American Heart Association, Council on the Kidney

American Federation for Medical Research

New York Academy of Sciences

American Association for the Advancement of Science

American Society of Nephrology

International Society of Nephrology

American Statistical Association

Oxygen Society

American Society for Biochemistry and Molecular Biology

(ASBMB)

American Chemical Society

American College of Physician (Fellow)

FACULTY POSITIONS HELD

Acting Instructor: U. of Washington School of Medicine 1986-1988

Seattle, WA

Associate Investigator, Dept. of Veterans Affairs

Assistant Professor of Medicine, U. of Washington Medical School 1988-1992

Seattle, WA

Research Associate, Dept. of Veterans Affairs

Clinical Assistant Professor of Medicine, U. of Washington Medical 1992-1994

School

Seattle, WA

Clinical Associate Professor of Medicine, U. of Washington Medical 1994-2000

School

Seattle, WA

TEACHING RESPONSIBILITIES

Renal Physiology and Pathophysiology Course, 1986-1992

University of Washington School of Medicine:

Lecture: Sodium and potassium metabolism

Small group leader: Fluid and electrolytes

Glomerular pathophysiology

Acute renal failure

Clinical nephrology

Introduction to Clinical Medicine II 1986-2000

University of Washington School of Medicine:

Clinical tutor (1986-1988)

Small group leader (ongoing through 2000)

Examination group (1989-1993)

Post-doctoral training, Division of Nephrology 1989-1991

University of Washington School of Medicine

Research training of post-doctoral fellow,

Margaret Thornton Eddy, M.D. in lipid biochemistry

and applications of lipid biochemistry to glomerular cell biology

(cf. American Heart Association grants below)

Post-doctoral training, Division of Nephrology 1990-1993

University of Washington School of Medicine

Research training of post-doctoral fellows, enrolled in

NIH Clinical Fellows Training Program.

Courses included Basic Science and Nephrology, Special

Studies in Fluid and Electrolyte Physiology, Acid-Base Balance,

Molecular Biology in Nephrology, Biochemistry and related

Topics in Nephrology, and Special topics in Lipid Biochemistry

Lectures, Biochemistry, Lipid Biology, Biotechnology 1988-1993

Seattle University, (Guest Lecturer)

Lectures, Biochemistry 211, University of Washington 1994

Biophysics of Lipid Membranes

ATTENDING RESPONSIBILITIES

Attending in Internal Medicine:

Veterans Affairs Medical Center, Seattle, WA 1986-1993

2-3 months/year

Harborview Medical Center, Seattle, WA 1993-1995

1 month/year

Attending in Hypertension

University of Washington Medical Center, 1984-1989

Hypertension Clinic

Full time (2 clinics/week)

Attending in Nephrology

Veterans Affairs Medical Center, Seattle, WA 1986-1993

2-3 months/year

Veterans Affairs Medical Center, Seattle, WA 1985-1992

Hypertension/Nephrology Clinic

Veterans Affairs Medical Center, Seattle, WA 1988-1992

Renal/pancreas Transplant Clinic

Harborview Medical Center, Seattle, WA 1993-1995

1 month/year

LOCUM TENENS

Staff Care, Inc. July, 2000

Northwest Transplant Nephrology Associates August, 2000 –

October, 2000

Interim Medical Director, Monroe Centralized Command September, 2000-

Monore Washington Correctional Centers October, 2000

Transplant and Nephrology Northwest Associates November, 2000-

December, 2000

Transplant and Nephrology Northwest Associates January, 2001-

February, 2002

May, 2002

June, 2002

PRIVATE PRACTICE

Napa Valley Nephrology & Internal Medicine Medical Group, Inc. 2002-2019

Chairman of Medicine, St Helena Hospital 2016-2018

Co-Director of Intensive Care Unit, St Helena Hospital, Napa Valley 2015-2017

St Helena Nephrology Clinic 2012-2019

HOSPITALIST

St Helena Hospital 2018-present

Sonoma Valley Hospital 2019-present

ATTENDING PRIVILEGES, FULL TIME

Seattle Veterans Affairs Hospital 1985-1993

Seattle, WA

Northwest Hospital 2002-2004

Swedish Hospital Medical Center 2000-2002

Seattle, WA

First Hill campus

Ballard campus

Providence Hospital

Vencor (Kindred) Hospital 2000-2002

Seattle, WA

Northwest Hospital 2000-2002

Memorial Hospital 2002

Modesto, CA

Queen of the Valley Medical Center 2002-present

Napa, CA

St. Helena Hospital 2002-present

St. Helena, CA

SPECIAL LOCAL RESPONSIBILITIES

Safety Committee, Medical Research, Seattle VAMC 1988-1992

Executive Committee, Medical Research, Seattle VAMC 1987-1990

Student Thesis Committee, U. of Washington School of Medicine 1989-1991

Admissions Committee, U. of Washington School of Medicine 1999-2000

REVIEWER

J.Clin Investigation, 1990-1992, 1995

J. Immunology, 1993-1995, 1996

J. Histochemistry & Cytochemistry, 1992-1996

Immunopharmacology, 1994

Blood, 1995-1997

Proceedings of the National Academy of Sciences, 1995, 1997

Cancer Research, 1993, 1995, 1998

J. Clinical Pharmacology, 1998

GRANT SUPPORT

Associate Investigator, Career Development, Dept. of Veterans Affairs 1986-1988

Effect of Bacterial Cell Wall Products on Mesangial Cell Activation

Research Associate, Career Development, Dept. of Veterans Affairs 1989-1993

Stimulation of Lipid Metabolism by Lipid A and Interleukin 1 in Human

Mesangial Cells

Northwest Kidney Foundation, Clinical Investigators Award 1988-1992

Effect of Lipid A, Interleukin 1, and Tumor Necrosis Factor on

Lipid Metabolism in Mesangial Cells

American Heart Association, Clinical Investigators Award 1990-1992

Cyclosporine A Interaction with Membranes and Lipid metabolism

In Human and Rat Mesangial Cells

Merit Review, Department of Veterans Affairs 1992-1993

Isolation and Characterization of Acyl CoA: Lyso-phosphatidic

Acid Acyl Transferase from Bovine Brain and Liver

PATENTS GRANTED (Internal number: patent number)

Modulation of cellular response to external stimuli (0103CA) 12/23/1992

Modulation of cellular response to external stimuli (0103SA: 01/27/1993

92/3808 S. Africa)

Modulation of cellular response to external stimuli (0103D: 12/17/1996

5585380 U.S.)

Method for preventing tissue injury from hypoxia (0203A: 09/25/1996

5581168 U.S.)

Method for inhibiting mast cell and basophil activation (1306) 03/10/1998

The effect of CT-1501R on neutrophil function and bacterial 05/16/1998

Killing (0203EP)

Sepsis, adult respiratory distress syndrome, and systemic 06/30/1998

Inflammatory response syndrome diagnostic (5,780,237 US)

Composition for wound healing and vascularization (1303A) pending

Composition for wound healing, neuron growth, and pending

Vascularization (1303WO)

Method for treating neoplastic diseases (1305) pending

Method for treating immune complex disease (0206) pending

Method for treating disease mediated by cellular proliferation 08/18/1998

In response to PDGF, EGF, FGF, and VEGF (5,795,898 US)

Neoplasia diagnostic method (1702) (US 5773300) 06/30/1998

Sepsis, adult respiratory distress syndrome and systemic 07/14/1998

Inflammatory response syndrome diagnostic (US 5780237)

Oxidized fatty acid diagnostic system for radiation exposure 03/31/2000

(1703) (5823356 US)

PATENTS GRANTED (Internal number: patent number) cont.:

Method for selectively inhibiting IL-2 signal transduction (1304A) 06/11/2001

Effects of novel lipoxin-related compounds on treatment of 04/10/2008

Inflammation

Methods of synthesis of novel lipoxin-related compounds 05/23/2008

BIOPHARMACEUTICAL EXPERIENCE

Co-director, Second Messenger and Lipid Biochemistry, 1992-1995

Cell Therapeutics, Inc.

One of the scientific founders of the corporation, assisting in ongoing

Determinations of mechanism of action of compounds of interest to corporation.

First focused interest of corporation on lipid metabolism, particularly that of

phosphatidic acid and diacylglycerol. Originally described association of

lyso-phosphatidic acid: acyl CoA acyltransferase (LPAAT) with inflammatory

processes and cytokines (Lipid A, IL-1), which has subsequently been confirmed

by cloning of enzyme. In addition, suggested that LPAAT modulation of PA acyl content

may affect tumor development. Also developed theories that corporate compounds

affected other PA-associated enzymes, including DG kinase and phospholipase

D (PLD) (confirmed by experiments performed by Roche Corporation).

Helped to initiate experiments suggesting that compounds of interest to corporation

were structural or direct inhibitors of enzymes such as DG kinase. Helped to associate

PA and DG levels in tumor cell lines with possible vulnerability of tumors to CTI compounds.

Assisted in setting up section of lipid biochemistry and design of laboratories, as well

as recruiting and personnel development for section.

Managed laboratory initially with 5 persons, growing to 12 persons, including two

Ph.D. level scientist and three M.S. level scientists.

Assisted in design of certain pharmaceutical compounds of interest to corporation

relating to structures of lipid compounds.

Initiated coordination between Clinical Affairs and Lipid Biochemistry sections,

developing clinical studies and protocols for biochemical/serum markers for effects of

lisofylline. Participated with Clinical Affairs department in writing protocols for all clinical

trials involving lisofylline and lipid compounds, as well as development of clinical trials with

biochemical markers. Served on Lisofylline Development Committee 1992-1995,

participated in writing IND for lisofylline.

Section management parameters:

Personnel budget ranged from $400,000 - $485,000.

Equipment budget of ca. $165,000 initial and $50,000 yearly.

Supply budget of ca. $125,000 - $210,000 yearly

Founders’ Award for achievement and entrepreneurial spirit, 1995.

Principal Scientist, Lipid Biology/Analytical Lipid Chemistry 1995-2000

Cell Therapeutics, Inc.

Demonstrated that compounds of interest to CTI affect serum free fatty acids, and

serum oxidized lipids, including hydroperoxyoctadecadienoic acids. Assisted in

development of methods for analyzing and isolating enzymes of interest to corporation,

including acyl CoA: lysophosphatidate acyltransferase (LPAAT) and phospholipase

D (PLD).

Managed laboratory with 14-22 persons, including five Ph.D. level scientists and

four M.S. level scientists.

Coordinated efforts in Clinical Chemistry analysis of plasma and serum FFA, and

serum/plasma oxidized FFA with clinical studies on lymphoma, leukemia, bone marrow

transplant, and acute lung injury patients.

Acted as coordinator between Clinical Affairs and Research department during

1995-1998 clinical studies, including (CTI studies) CT 1014, 1015, 1016, 1018, 1028,

1031, 1032, 1034, 1038, 1040.

Also undertook statistical analyses for clinical chemistry studies during this period.

Management parameters:

Personnel budget ranging from $850,000 - $985,000.

Equipment budget of ca. $400,000 initial and $75,000 yearly.

Purchase/lease of electrospray mass spec. 1998 ($400,000)

Supply budge of ca. $225,000 - $300,000 yearly.

SUMMARY OF EXPERTISE:

Scientific: Enzyme assays, lipid biochemistry

Drug development: drug screening for LPAAβ, PLD

Drug development: rational drug design (CT2584, CT2576, CT3501)

Electron microscopy, scanning

Electron microscopy, transmission

In vitro models for inflammation, ischemia/reperfusion, oxidation, acute renal failure

In vitro models for inflammatory, ischemia/reperfusion, oxidation, acute renal failure

2-dimensional gel electrophoresis

Biophysics (lipid membrane studies):

Fluroescence spectroscopy

Fluorescence amisotrophy

Fourier transform infrared spectroscopy (FTIR)

Differential scanning calorimetry (DSC)

Nuclear magnetic resonance (NMR)

Mass spectrometry (MS: MS/MS; MRM)

Analytical and clinical chemistry:

Normal and reverse phase high performance liquid chromatography (HPLC)

Chiral HPLC

Gas-liquid chromatography

Gas chromatography

Mass spectrometry (Fast-atom bombardment; electrospray, MALDI-TOF)

Medicinal Chemistry:

Rational drug design for lipid-related compounds.

Clinical: General internal medicine

Intensive care medicine

Hypertension

Nephrology:

Hemodialysis

Hemofiltration

CVVH

CAVH

CVVH/HD

Renal transplantation

Clinical studies, acute renal failure

Clinical studies, hypertension

Clinical studies, clinical chemistry

Clinical study management

Clinical study analysis (statistical)

Clinical drug development, including IND

Intellectual Property:

Composition of matter patents

Construction of intellectual property positions

Patent development for lipid and lipid-related compounds

Patent development for design of lipid-related compounds

CONSULTING EXPERIENCE

D.C. Steffens Capital Group July, 1999

Irvington, NY

Medical and Biotechnology Consultant

S.W. Chiles Capital Group November, 1999

New York, NY

Medical and Biotechnology Consultant

Lumicyte Corporation December, 1999

San Francisco, CA

Medical Consultant

Institute of Lipid Studies December, 1999

Seattle, WA

Founder, Research Director, Medical Consultant

Chalone Corporation August, 2001

Boston, MA./New York, NY

Medical/Biochemistry Consultant

Resolvyn Corporation November, 2001

New York, NY

Medical/Biochemistry Consultant

WORLD LANUGUAGE SPOKEN

FLUENT: Russian and German

SOME FLUENCY: Hebrew

UNDERSTANDING (reading): French and Yiddish

Contact this candidate